Tim Watkins, CMO and Head of Development at Contineum Therapeutics ($CTNM), sold shares on the open market four times over the past year, totaling about $149,000. His most recent CTNM insider sale occurred on March 2, 2026. These transactions rank 8,996th among 11,678 insiders in our database, well below the average sale value of $8.6 million across 6.37 transactions per insider. Watkins made no open market purchases in the last 365 days.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 2, 2026 | Contineum Therapeutics, Inc. | $CTNM | Watkins Tim | CMO & Head of Development | M | Class A Common Stock | 3611 | $4.50 | 3,611.0000 | 28,115,548 | 9999.99% | 0.01% |
| March 2, 2026 | Contineum Therapeutics, Inc. | $CTNM | Watkins Tim | CMO & Head of Development | M | Stock Option (right to buy) | 3611 | $0.00 | 249,167.0000 | 28,115,548 | 1.43% | 0.01% |
| March 2, 2026 | Contineum Therapeutics, Inc. | $CTNM | Watkins Tim | CMO & Head of Development | S | Class A Common Stock | 3611 | $15.02 | 0.0000 | 28,115,548 | 100.00% | 0.01% |
| Jan. 28, 2026 | Contineum Therapeutics, Inc. | $CTNM | Watkins Tim | CMO & Head of Development | S | Class A Common Stock | 2800 | $14.09 | 811.0000 | 28,115,548 | 77.54% | 0.01% |
| Jan. 28, 2026 | Contineum Therapeutics, Inc. | $CTNM | Watkins Tim | CMO & Head of Development | M | Class A Common Stock | 3611 | $4.50 | 3,611.0000 | 28,115,548 | 9999.99% | 0.01% |
| Jan. 28, 2026 | Contineum Therapeutics, Inc. | $CTNM | Watkins Tim | CMO & Head of Development | S | Class A Common Stock | 811 | $14.48 | 0.0000 | 28,115,548 | 100.00% | 0.00% |
| Jan. 28, 2026 | Contineum Therapeutics, Inc. | $CTNM | Watkins Tim | CMO & Head of Development | M | Stock Option (right to buy) | 3611 | $0.00 | 252,778.0000 | 28,115,548 | 1.41% | 0.01% |
| Jan. 30, 2026 | Contineum Therapeutics, Inc. | $CTNM | Watkins Tim | CMO & Head of Development | A | Stock Option (right to buy) | 160000 | $0.00 | 160,000.0000 | 28,115,548 | 9999.99% | 0.57% |
| Dec. 29, 2025 | Contineum Therapeutics, Inc. | $CTNM | Watkins Tim | CMO & Head of Development | M | Class A Common Stock | 3611 | $4.50 | 3,611.0000 | 28,115,548 | 9999.99% | 0.01% |
| Dec. 29, 2025 | Contineum Therapeutics, Inc. | $CTNM | Watkins Tim | CMO & Head of Development | M | Stock Option (right to buy) | 3611 | $0.00 | 256,389.0000 | 28,115,548 | 1.39% | 0.01% |
| Dec. 29, 2025 | Contineum Therapeutics, Inc. | $CTNM | Watkins Tim | CMO & Head of Development | S | Class A Common Stock | 3611 | $12.06 | 0.0000 | 28,115,548 | 100.00% | 0.01% |
| April 28, 2025 | Contineum Therapeutics, Inc. | $CTNM | Watkins Tim | CMO & Head of Development | A | Stock Option (right to buy) | 26000 | $0.00 | 26,000.0000 | 19,352,859 | 9999.99% | 0.13% |
| April 28, 2025 | Contineum Therapeutics, Inc. | $CTNM | Watkins Tim | CMO & Head of Development | A | Stock Option (right to buy) | 260000 | $0.00 | 260,000.0000 | 19,352,859 | 9999.99% | 1.34% |